Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
ARS Pharmaceuticals, Inc. develops and commercializes neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s news commonly covers U.S. commercialization, product labeling, international approvals and licensing relationships for neffy, which is marketed as EURneffy in the European Union and the United Kingdom and under a separate trade name in China.
Recurring updates also include quarterly and annual financial results, clinical and scientific presentations on intranasal epinephrine, school-access programs, manufacturing and supply responsibilities for partners, and investor conference activity. The company’s allergy-treatment focus makes regulatory decisions, product access, clinical data and commercial launch progress central themes in its public announcements.
ARS Pharmaceuticals (Nasdaq: SPRY) reported Q1 2026 revenue of $22.7 million, including $17.5 million in neffy U.S. net product revenue. Net loss was $60.6 million, with $201.0 million in cash and investments.
Updates included neffy label expansion, Health Canada and EU approvals, broader U.S. access initiatives, sales force expansion to 148 representatives, and progress in the Phase 2b chronic spontaneous urticaria trial, with interim data expected in Q4 2026.
ARS Pharmaceuticals (Nasdaq: SPRY) appointed industry veteran Donn Casale as President, effective June 1, 2026, while Richard Lowenthal remains CEO.
Casale will lead global commercial operations for neffy (epinephrine nasal spray) and support expansion into chronic spontaneous urticaria, drawing on prior experience scaling HEPLISAV-B to over $300 million annualized revenue.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Friday, May 15, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss first quarter 2026 financial results and business highlights. Dial-in details require event registration. A webcast replay will be available for 30 days.
ARS Pharmaceuticals (Nasdaq: SPRY) announced Health Canada approval of neffy 2 mg (epinephrine nasal spray) for emergency treatment of allergic reactions (anaphylaxis) in adults and children ≥30 kg. ARS has received $155 million in upfront and milestones from ALK and may receive up to $310 million more plus tiered double‑digit royalties. ALK Canada expects availability in summer 2026. ARS will manufacture and supply neffy in Canada and plans a filing for a 1 mg pediatric dose by summer 2026.
ARS Pharmaceuticals (Nasdaq: SPRY) announced FDA approval to remove the age requirement for neffy 1 mg, allowing use in all children and adults who weigh ≥33 lbs. (15 kg) for emergency treatment of Type 1 allergic reactions, including anaphylaxis.
The label also adds storage guidance (blister or neffy carrying case); ARS will include a carrying case in each prescription carton beginning this summer.
ARS Pharmaceuticals (NASDAQ: SPRY) reported full-year 2025 revenue of $84.3M including $72.2M of U.S. net product revenue from neffy, and Q4 2025 revenue of $28.1M. Full-year SG&A was $230.1M and net loss was $171.3M. The company held $245.0M in cash and short-term investments at year-end and expects that cash to fund operations through anticipated cash-flow break-even. Commercial progress includes expanded payor discussions, a January 2026 DTC ad, salesforce growth to 150 reps in Q2 2026, and regulatory approvals in China, Australia and a CHMP positive opinion for EURneffy 1 mg.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and business highlights.
Management will also participate in investor conferences on Feb 25, Mar 11, and Mar 22, 2026; webcasts and replay access are available via the company’s Events & Presentations page for 30 days.
ARS Pharmaceuticals (Nasdaq: SPRY) will present clinical and economic data on neffy® (epinephrine nasal spray) at the AAAAI Annual Scientific Meeting, Feb 27–Mar 2, 2026. Five posters, one HCP case report and two ALK late-breakers cover pharmacokinetics, usability, preference and health‑economic analyses.
Company said neffy 2 mg shows similar exposure to 0.5 mg intramuscular injection, longer shelf life versus autoinjectors, and pharmacoeconomic models indicate increased value when accounting for needle aversion.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that the EMA CHMP has adopted a positive opinion recommending expansion of EURneffy marketing authorization to include a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children weighing ≥15 kg to <30 kg.
Following European Commission approval, ALK-Abelló will distribute EURneffy across EU member states, Iceland, Liechtenstein and Norway; this complements the August 2024 EC approval of EURneffy 2 mg for patients ≥30 kg and recent regulatory activity in the U.S., Canada (anticipated), Japan, China and Australia.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that California K-12 schools are now eligible for the neffyinSchools program, which provides free needle-free neffy® epinephrine nasal spray for emergency use.
The program, launched in January 2025, now spans 24 states with more than 8,000 participating schools; ARS Pharma has donated nearly 45,000 doses to date. Eligible public and private K-12 schools can request two cartons (four single-use doses) of neffy 1 mg and 2 mg at no cost and may receive replacements after use or expiration.